课题基金 / 基金详情

项目摘要

项目成果

William C. Hahn的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):我们最近对卵巢癌细胞系中必需基因的基因组规模调查,加上卵巢癌基因组的综合表征,确定了PAX8转录因子的表达是大多数卵巢肿瘤的关键易感性。PAX8是一对盒子转录因子家族的成员,在女性输卵管和输卵管的发育过程中表达,被认为是卵巢癌的起源。PAX8在大多数卵巢肿瘤或细胞系中过表达或扩增,表明许多卵巢癌细胞利用PAX8转录程序维持其存活和增殖。我们发现PAX8是卵巢癌细胞系存活所需的最高基因,而不是正常卵巢细胞或来自各种其他谱系的细胞。表征卵巢肿瘤这种新型依赖性背后的潜在生物学机制需要pax8特异性化学探针,然而此类探针迄今尚未报道。本项目重点是鉴定特异性抑制表达PAX8的卵巢癌细胞存活的PAX8活性小分子抑制剂。这样的抑制剂不仅有利于调查
英文摘要
DESCRIPTION (provided by applicant): Our recent genome-scale survey of genes essential in ovarian cancer cell lines coupled with the comprehensive characterization of ovarian cancer genomes pinpointed the expression of the PAX8 transcription factor as a critical vulnerability of the majority of ovarian tumors. PAX8 is a member of the paired- box family of transcription factors expressed during the development of the female M¿llerian ducts and in the fallopian tube, which is considered the origin of ovarian carcinomas. PAX8 is overexpressed or amplified in most ovarian tumors or cell lines indicating that many ovarian cancer cells have co-opted PAX8 transcriptional program to maintain their survival and proliferation. We found that PAX8 was the highest ranked gene required for the survival of ovarian cancer cell lines but not normal ovarian cells or cells from a variety of other lineages. Characterizing the underlying biological mechanisms behind this novel dependency of ovarian tumors requires PAX8-specific chemical probes, however such probes have not been reported to date. This project focuses on the identification of small-molecule inhibitors of PAX8 activity that specifically inhibit the survivalof ovarian cancer cells expressing PAX8. Such inhibitors will not only facilitate the investigation of the biological mechanism behind the addiction of ovarian cancers to PAX8 but may also serve as useful starting points for future therapeutic avenues of development. To identify inhibitors of PAX8 activity we have developed and validated a cell-based Luc reporter gene assay in 384-well format that measures PAX8 activity in ovarian cancer cells. We selected an ovarian cancer cell line (from a panel of 25 well-characterized ovarian cancer cell lines) that expresses high levels of PAX8 and is strongly dependent on PAX8 expression, and thus is highly relevant to PAX8 biology. Compounds that suppress PAX8 activity will be subjected to two counter screens to remove: i) non-specific inhibitors of transcription; ii) Luc inhibitors; and iii) generally cytooxic compounds. We wil then characterize compounds that preferentially reduce the survival of PAX8-dependent versus independent cancer cells. Top scoring compounds will then be optimized to achieve the desired selectivity, efficacy and potency. As a short-term goal, we will use these compounds as probes to elucidate the molecular basis of PAX8 essentiality in ovarian tumors. In parallel, the direct binding targets will be identified using mass-spectrometry- based proteomics, providing important knowledge on upstream regulators and downstream effectors of PAX8. Since our preliminary work suggests that PAX8 expression represents a clear biomarker that predicts sensitivity of ovarian tumors to PAX8 suppression, we envision using these PAX8 modulators in xenograft models of ovarian cancer as we work towards a longer-term goal of translating these findings into therapeutic opportunities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers
  • 批准号:
    10627744
  • 项目类别:
  • 资助金额:
    $65.12万
  • 财政年份:
    2022
  • 负责人:
    William C. Hahn
  • 依托单位:
Novel genetic dependencies in VRK2 methylated glioblastoma multiforme
  • 批准号:
    10046375
  • 项目类别:
  • 资助金额:
    $17.8万
  • 财政年份:
    2020
  • 负责人:
    William C. Hahn
  • 依托单位:
Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models
  • 批准号:
    10004385
  • 项目类别:
  • 资助金额:
    $100.49万
  • 财政年份:
    2020
  • 负责人:
    William C. Hahn
  • 依托单位:
Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens
  • 批准号:
    10250566
  • 项目类别:
  • 资助金额:
    $56.84万
  • 财政年份:
    2017
  • 负责人:
    William C. Hahn
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: